Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42572   clinical trials with a EudraCT protocol, of which   7010   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-000142-35
    Sponsor's Protocol Code Number:UC-0160/1105
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-08-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2012-000142-35
    A.3Full title of the trial
    A Prospective randomized phase III study of Androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without local radiotherapy with or without ABIRATERONE ACETATE and PREDNISONE in patients with Metastatic Hormone-Naïve Prostate Cancer.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    _
    A.3.2Name or abbreviated title of the trial where available
    GETUG AFU 21-PEACE 1
    A.4.1Sponsor's protocol code numberUC-0160/1105
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUNICANCER
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJANSSEN-CILAG
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUNICANCER
    B.5.2Functional name of contact pointIsabelle Rieger, Project Leader
    B.5.3 Address:
    B.5.3.1Street Address101, rue de Tolbiac
    B.5.3.2Town/ cityParis cedex 13
    B.5.3.3Post code75654
    B.5.3.4CountryFrance
    B.5.4Telephone number+33180501599
    B.5.5Fax number+33185343379
    B.5.6E-maili-rieger@unicancer.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Abiraterone Acetate
    D.2.1.1.2Name of the Marketing Authorisation holderJanssen-Cilag International NV
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNABIRATERONE ACETATE
    D.3.9.1CAS number 154229-18-2
    D.3.9.4EV Substance CodeSUB31647
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    metastatic hormone-naïve prostate cancer
    E.1.1.1Medical condition in easily understood language
    prostate cancer
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10036909
    E.1.2Term Prostate cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of abiraterone acetate and prednisone in patients
    with metastatic hormone-naïve prostate cancer treated by androgen
    deprivation therapy and docetaxel (with or without local radiotherapy)
    in terms of overall survival (OS) and radiographic progression-free
    survival (rPFS).
    E.2.2Secondary objectives of the trial
    Castration resistance-free survival (CRFS)
    • Serious Genitourinary event-free survival (S-GU-EFS)
    • Prostate cancer specific survival
    • Time to next skeletal-related event
    • PSA response rate
    • Prospective correlative study of PSA response/progression at 8
    months after initiation of ADT
    • Time to pain progression
    • Time to chemotherapy for CRPC
    • Quality of life
    • Toxicity (with a specific focus on the use of long-term low-dose
    steroids)
    • Changes in bone mineral density (BMD)
    • Correlation of biomarkers with outcome, including the prognostic and
    predictive value on OS, rPFS and CRFS of a neuro-endocrine
    differentiation of the prostate cancer in the pathological specimen
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Biologic ancillary study : constitution of a collection (France only)
    Imaging ancillary study
    E.3Principal inclusion criteria
    1. Histologically or cytologically confirmed adenocarcinoma of the prostate,
    2. Metastatic disease documented by a positive bone scan (any technique) or a CT scan or an MRI. For patients with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes (lymph nodes located above the iliac bifurcation) can be included if they have either:
    - At least one extra-pelvic lymph node ≥ 2 cm
    or
    - extra-pelvic lymph node (s) ≥ 1 cm if the patients also have at least one pelvic lymph node ≥ 2 cm
    3. Patients with ECOG ≤ 1 (patient with PS 2 due to bone pain can be accrued in the trial),
    4. Life expectancy of at least 6 months,
    5. Male aged ≥ 18 years old and ≤80 years old,
    6. Hematology values:
    - Hemoglobin ≥ 10.0 g/dL,
    - Platelet count ≥ 100,000/μL,
    - Neutrophil ≥ 1500 cells/mm3
    7. Biochemistry values:
    - Renal function: serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min,
    - Serum potassium ≥ 4 mmol/L,
    - Liver function: Serum bilirubin ≤ 1.5 x ULN (except for patients with documented Gilbert’s disease); AST and ALT ≤ 1.5 x ULN (and ≤ 5 ULN in case of liver metastases); ALP ≤ 2.5 x ULN (in case of bone metastasis, ALK-P<1000U/L if bilirubin is normal),
    8. Patients must have received ADT for a maximum of 3 months before
    randomization and there must be a minimum of 6 weeks between the start of ADT and
    the start of Docetaxel,
    9. Patients willing and clinically fit to receive Docetaxel, which is defined by the following :
    - Patients respecting all inclusion and exclusion criteria
    And
    - Patients with no contraindication to docetaxel according to the SmPC of the drug
    And
    - Patients presenting all medical requirements to receive docetaxel according to the investigator’s opinion
    10. Patients might have received previous radiation therapy directed to bone lesions,
    11. Patients able to take oral medication,
    12. Patients who have received the information sheet and signed the informed consent form,
    13. Male patients who will receive docetaxel and/or abiraterone acetate and have partners of childbearing potential and/or pregnant partners are advised to use a method of birth control in addition to an adequate barrier protection (condoms) as determined to be acceptable by the study doctor during the treatment period and for 4 weeks after the last dose of abiraterone acetate and/or for 6 months after the last dose of docetaxel.
    14. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
    15. Patients with a public or a private health insurance coverage, according to local laws for participation in clinical trials,
    E.4Principal exclusion criteria
    1. Patients with previous definitive local treatment directed to the prostate primary cancer (radiotherapy, brachytherapy, radical prostatectomy, ultrasound, cryotherapy, or other). A previous trans-urethral resection of the prostate (TURP) and previous local treatments of metastasis are allowed,
    2. Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate cancer,
    3. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg prednisone/prednisolone twice daily,
    4. Active infection or other medical condition for which prednisone/prednisolone (corticosteroid) use would be contraindicated,
    5. Previously treated with ketoconazole for prostate cancer for more than 7 days,
    6. Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of randomization,
    7. Hypertension not controlled by an anti-hypertensive treatment (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg), 3 consecutive measures taken 5 minutes apart),
    8. Severe or moderate hepatic impairment (Child – Pugh class C),
    9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert’s disease),
    10. History of pituitary or adrenal dysfunction,
    11. Clinically known significant heart disease in the past 6 months as
    evidenced by myocardialinfarction, or arterial thrombotic events , severe
    or unstable angina, or New York Heart association (NYHA) Class II-IV heart
    disease or cardiac ejection fraction measurement of < 50% at baseline,
    12. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,
    13. Patients with unstable pulmonary disease (eg. Pulmonary embolism),
    14. Pathological finding consistent with small cell carcinoma of the prostate,
    15. History of malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 24 months,
    16. Known allergies, hypersensitivity or intolerance to the study drugs or excipients or docetaxel,
    17. Administration of an investigational therapeutic within 30 days of randomization,
    18. Patients already included in another therapeutic trial involving an experimental drug (patient in a non-experimental trial with no modification of the patient’s care can be
    included),
    19. Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition which, in the opinion of the investigator, would preclude participation in this trial. Those conditions should be discussed with the patient before registration in the trial,
    20. Individual deprived of liberty or placed under the authority of a tutor.

    Additional criteria for patients receiving docetaxel:
    21. Patients with impaired vision should undergo a prompt and complete ophtalmologic examination. Patients with Cystoid Macular Oeadema cannot be included due to a
    potential risk of deterioration associated with docetaxel, the patient should not receive
    docetaxel.
    22. Concomitant use of strong CYP3A4 inhibitors ( clarithromyin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin)
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoints of this study are overall survival (OS) and
    radiographic progression-free survival (rPFS).
    Overall survival (OS) is defined as the time from randomization to the
    time of death from any cause and radiographic progression-free survival
    (rPFS) defined as the time from randomization to the radiographic
    progression or death.
    Radiographic progression is defined according to an adapted version of
    Prostate Cancer Working Group 2 (PCWG2) criteria (either a RECISTprogression in case of measurable lesions or the appearance of at least 2
    new lesions on bone scan). In contrast to PCWG2 criteria, a second bone
    scan is not mandatory to confirm radiographic progression. The date of
    radiographic progression will be the date of progression as per the above
    definition.
    It should be noted that a patient can enter the post-CRPC follow up if
    progressive disease has been established by a PSA rise only, without
    radiographic progressive disease. In this scenario, imaging monitoring
    will continue every 6 months and radiographic progression may be
    established later.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Not applicable
    E.5.2Secondary end point(s)
    •Castration resistance free survival (CRFS) is defined as the time from
    randomization to the castrate-resistant (CRPC) status or death from any
    cause.
    CRPC is defined by cancer progression (either a confirmed PSA rise or a
    radiographic progression) with serum testosterone being at castrated
    levels (<0.50 ng/mL).
    A PSA rise is defined by an increased serum PSA on 2 different
    measurements, confirmed by a third measurement (measurement
    A<B<C). The minimum level of the third PSA measurement should be 0.5
    ng/mL.
    A minimum delay of 2 weeks is recommended between measurements A
    and B. A delay of 3 months is recommended between measurement B
    and C. The date of progression will be the date of measurement C.
    Serum testosterone should be obtained when PSA measurement C is
    done.
    In case of progression while serum testosterone is > 0.50 ng/mL, the
    patient should be rapidly submitted to another method of castration
    (chemical or surgical) and PSA + testosterone should be tested again to
    confirm or not CRPC progression.
    Radiographic progression is defined as per the above definition.
    For patients alive without radiographic progression or confirmed PSA
    rise at the time of analysis, data will be censored at the date of last
    follow-up.
    • Serious Genitourinary event-free survival (S-GU-EFS) is defined as
    the time from randomization to the first occurrence of one of the
    following events : urinary retention with need for a urinary catheter,
    suprapubic catheter, double J stent, nephrostomy, treatment of the
    prostate by radiotherapy (except that by randomization in arms C and D)
    or trans-urethral resection of the prostate (TURP), prostatectomy or
    death. It is assumed that prostate radiotherapy (and abiraterone) may
    prevent or delay these serious genitourinary events. For patients alive
    without Serious Genitourinary Event at the time of analysis, data will be
    censored at the date of last follow-up.
    • The prostate cancer-specific survival will be calculated from the date
    of randomization to the date of the death due to prostate cancer. For
    patients alive at the time of analysis, or who died from a cause other
    than prostate cancer, data will be censored at the date of last follow-up,
    • The time to next skeletal-related event will be defined by either a
    fracture or a bone pain requiring radiation therapy or a spinal cord
    compression or a preventive surgery to the bones. Events will be
    evaluated by investigators. No systematic X-Ray will be perform
    • PSA response rate will be assessed using a waterfall plot. Complete
    PSA response is defined by an undetectable serum PSA level (<0.2
    ng/mL).
    • The prospective correlative study of PSA response/progression will
    be evaluate at 8 months after initiation of ADT,
    The time to pain progression will be evaluated by questionnaires
    (BPI-SF) and calculated from the date of randomization to the first date
    the patient experiences a BPI-SF increase by ≥ 30% from baseline in the
    BPI-SF worst pain intensity (items 3) observed at 2 consecutive
    evaluations ≥ 4 weeks apart.
    • The time to chemotherapy will be calculated from the date of
    randomization to the date of the first use of chemotherapy treatment for
    CRPC
    • Quality of life will be evaluated using the FACT-P and QLQ-C30
    questionnaires.
    • Toxicity (with a specific focus on the use of long-term low-dose
    steroids) will be evaluated according to NCI-CTCAE v4.0
    • Bone loss will be evaluated by bone mineral density (BMD) to
    determine if patients receiving Abiraterone acetate and prednisone
    and/or radiotherapy have an increase risk
    • Correlation of biomarkers with outcome, including the prognostic and
    predictive value on OS, rPFS and CRFS of a neuro-endocrine
    differentiation of the prostate cancer in the pathological specimen.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Not applicable
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA110
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Denmark
    France
    Germany
    Greece
    Ireland
    Israel
    Italy
    Netherlands
    Poland
    Romania
    Spain
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years17
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years17
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 586
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 587
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state54
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1173
    F.4.2.2In the whole clinical trial 1173
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-09-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-12-01
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA